Cosylab and Heron Neutron Medical Corp. Sign Letter of Intent to Advance Global Deployment of Accelerator-Based BNCT Systems
10.6.2026 11:30:00 CEST | Business Wire | Press Release
Cosylab and Heron Neutron Medical Corp. announced today, 10 June 2026, the signing of a Letter of Intent to establish a strategic framework for joint market development to support the global deployment of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) systems.
The collaboration aims to accelerate the development and integration of sophisticated software solutions for use with AB-BNCT while strengthening AB-BNCT's international market access and business development. By combining Cosylab's proven expertise in mission-critical software and complex system integration with Heron's end-to-end BNCT platforms, the partnership aims to drive broader global clinical adoption of this highly targeted cancer treatment modality.
"AB-BNCT is emerging as one of the most promising approaches for treating difficult-to-treat and recurrent cancers," said Mark Pleško, Chief Executive Officer of Cosylab. "This collaboration reinforces our strategic focus on advancing radiation therapy technologies and expanding our reach in the Asia-Pacific region and beyond. We are committed to delivering impactful joint projects with Heron that accelerate market readiness and clinical adoption."
"This agreement represents a key step in Heron's international growth strategy," underlined Shen Hsiao-Lien, General Manager of Heron Neutron Medical Corp. "Working with Cosylab will strengthen our cross-regional capabilities and support the rapid scaling of AB-BNCT solutions in markets worldwide."
About Cosylab: Cosylab (www.cosylab.com) develops software and control systems for the world's most demanding scientific and medical technology environments, including particle accelerators, radiation therapy systems, fusion research facilities, and semiconductor equipment. Founded in 2001 and headquartered in Ljubljana, Slovenia, Cosylab operates globally across research institutions, hospitals, and industrial facilities.
About Heron Neutron Medical Corp.: Heron Neutron Medical Corp. develops integrated Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) systems that encompass accelerator technologies, neutron beamlines, treatment platforms, and full clinical workflow integration. The company is dedicated to advancing innovative cancer treatment solutions and expanding global access to BNCT.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260609620358/en/
Contacts
Contact (Cosylab): Petra Balažic, petra.balazic@cosylab.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region10.6.2026 13:47:00 CEST | Press Release
GENESIS Pharma, a leading regional biopharma company focused on the commercialization of innovative medicines in Europe, today announced the expansion of its longstanding commercial partnership with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), the leading RNAi therapeutics company. The extended agreement broadens the geographical reach of the collaboration to include four Nordic markets -Denmark, Finland, Norway, and Sweden- alongside the thirteen markets in Southeast Europe already within the scope of the partnership. GENESIS Pharma shall commercialize a portfolio of RNAi therapeutics for serious cardiomyopathy conditions and rare genetic diseases across this expanded territory. The partnership, established in 2019 for Southeast Europe, has progressively evolved to encompass a broader portfolio and geographic footprint, covering Greece, Cyprus, Bulgaria, Romania, Slovenia, Croatia, Serbia, Bosnia and Herzegovina, Albania, the Republic of North Macedonia, Montenegro, Malta, and Kosovo
AI-Driven Upgrade Cycle Expected to Fuel 8% Telecom Growth in 2026, NIQ Forecasts10.6.2026 13:00:00 CEST | Press Release
NIQ (NYSE: NIQ), a global leader in consumer intelligence, today released its 2026 Smartphone Forecast showing that an AI-driven upgrade cycle is expected to fuel 8% growth in the global telecom sector in 2026. As manufacturers accelerate investment in on-device AI and connected device ecosystems, consumers are increasingly prioritizing intelligence functionality, seamless integration, and premium experiences when choosing their next smartphone. The forecast suggests relatively stable conditions across the broader technology and durables market, with growth increasingly concentrated in premium segments. Europe is showing early signs of a new replacement cycle after two weaker years, while China is showing signals of modest growth despite subsidy rollbacks and a challenging comparison base. Insights from Mobile World Congress 2026 suggest a broader industry shift: smartphones are evolving from standalone communication devices into intelligent platforms that connect and orchestrate consu
Opensignal Expands Subscriber Analytics Solution, Available Globally10.6.2026 13:00:00 CEST | Press Release
Opensignal® today announced the global availability of Opensignal Subscriber Analytics™, extending the solution to operators across Europe, Asia Pacific, Middle East, Africa, and the Americas, subject to market-specific availability. Operators can contact Opensignal directly to confirm availability details in their specific markets of interest. Opensignal Subscriber Analytics measures competitive subscriber switching between operators at the local market level, alongside base market share by operator and region, using the same methodology Opensignal applies across its full measurement platform. Opensignal draws that measurement from hundreds of millions of subscriber devices globally. Until now, this capability has been available to operators in the United States and Canada. The global expansion makes it accessible to operators across all regions Opensignal serves. "Operators have strong visibility into their own network and commercial performance, but almost none for their competitors
Data Center World Unveils the Inaugural Data Center World Europe 202610.6.2026 13:00:00 CEST | Press Release
Data Center World, the premier event for the global data center ecosystem, unveils the launch of Data Center World Europe. Today, Data Center World Europe announces the Conference Agenda for the inaugural event. Over two days, Data Center World Europetackles the industry’s most urgent challenge: transforming Europe's data centre energy landscape. The event brings together leading operators, technologists, cloud providers, hyperscalers and energy management innovatorsto exchange actionable strategies and groundbreaking insights that drive measurable results. Attendees will leave equipped to overcome energy bottlenecks and drive the development of an AI-ready, sustainable future. Data Center World Europe takes place 13-14 October 2026 at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It will be co-located with the leading global network infrastructure event NetworkX. Register to attend here. Tara Gibb, Senior Director, Data Center World Europe said, “As the demand for A
SES to conduct share buyback transaction via acquisition of FDRs to meet obligations under its employee incentive programs10.6.2026 12:56:00 CEST | Press Release
SES has decided to launch a buyback transaction for shares via acquisition of fiduciary depositary receipts (FDRs) to meet obligations under SES’s Equity Based Compensation Plan (EBCP). These FDRs will be repurchased on the basis of Article 430-15(3) of the law of 10 August 1915 on commercial companies, as amended, and will not be counted towards the 10% limit as authorized during the annual general meeting of shareholders held on April 2, 2026. Under this share buyback transaction via acquisitions of FDRs, SES may acquire up to 2,967,519 FDRs (ISIN LU0088087324) at market price for an aggregate amount not exceeding EUR 31,158,949.50. The share buyback transaction via acquisition of FDRs is expected to be completed before the date of the next annual general meeting of shareholders or sooner if the maximum number of repurchased shares is reached earlier. The buyback will be conducted in accordance with applicable rules and regulations, including the Market Abuse Regulation 596/2014 and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom